Biomarkers for Oncology
JH · Effective Oct 1, 2015
400 active Medicare policies list 81479, and 88 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
Showing 100 of 400
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
J9 · Effective Apr 11, 2016
J9 · Effective Jul 17, 2023
JH · Effective Jul 17, 2023
JL · Effective Jul 17, 2023
J15
88 policies from 10 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Showing 10 of 24 · All Ambetter policies
| Policy | Effective | Status of 81479 |
|---|---|---|
| Concert Genetic Testing Oncology: Algorithmic Assays | Not recorded | Referenced |
| Concert Genetic Testing Oncology: Cancer Screening and Surveillance | Not recorded | Referenced |
| Concert Genetic Testing Oncology: Hematologic Malignancy | Not recorded | Referenced |
| Concert Genetic Testing Oncology: Solid Tumor Molecular Diagnostics |
J5
J15 · Effective Aug 10, 2026
JE · Effective Aug 10, 2026
JF · Effective Aug 10, 2026
JJ · Effective Aug 10, 2026
JM · Effective Aug 10, 2026
J5 · Effective Aug 10, 2026
J8 · Effective Aug 10, 2026
J15 · Effective Sep 22, 2024
JE · Effective Sep 22, 2024
JF · Effective Sep 22, 2024
JJ · Effective Sep 22, 2024
JM · Effective Sep 22, 2024
J5 · Effective Sep 22, 2024
J8 · Effective Sep 22, 2024
J15 · Effective Aug 17, 2025
JE · Effective Aug 17, 2025
JF · Effective Aug 17, 2025
JJ · Effective Aug 17, 2025
JM · Effective Aug 17, 2025
J5 · Effective Aug 17, 2025
J8 · Effective Aug 17, 2025
J15 · Effective May 13, 2019
JE · Effective Jun 3, 2019
JF · Effective Jun 3, 2019
JJ · Effective Apr 8, 2019
JM · Effective Apr 8, 2019
J5 · Effective Apr 15, 2019
J8 · Effective Apr 15, 2019
J15 · Effective Aug 21, 2022
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Jun 24, 2019
JE · Effective Feb 10, 2019
JF · Effective Feb 10, 2019
JJ · Effective Dec 3, 2018
JM · Effective Dec 3, 2018
J5 · Effective Aug 12, 2019
J8 · Effective Aug 12, 2019
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J15 · Effective Aug 6, 2023
JE · Effective Aug 6, 2023
JF · Effective Aug 6, 2023
JJ · Effective Aug 6, 2023
JM · Effective Aug 6, 2023
J5 · Effective Aug 13, 2023
J8 · Effective Aug 13, 2023
JE · Effective Aug 18, 2024
JF · Effective Aug 18, 2024
JJ · Effective Aug 18, 2024
JM · Effective Aug 18, 2024
J5 · Effective Aug 18, 2024
J8 · Effective Aug 18, 2024
J15 · Effective Oct 13, 2024
JE · Effective Sep 22, 2024
JF · Effective Sep 22, 2024
JJ · Effective Sep 22, 2024
JM · Effective Sep 22, 2024
J5 · Effective Sep 22, 2024
J8 · Effective Sep 22, 2024
J15 · Effective Jul 17, 2022
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J15 · Effective Jun 4, 2023
JE · Effective May 28, 2023
JF · Effective May 28, 2023
| Not recorded |
| Referenced |
| Concert Genetic Testing: Cardiovascular | Not recorded | Referenced |
|---|
| Concert Genetic Testing: Endocrinology | Not recorded | Referenced |
|---|
| Concert Genetic Testing: Gastroenterology | Not recorded | Referenced |
|---|
| Concert Genetic Testing: Hematology | Not recorded | Referenced |
|---|
| Concert Genetic Testing: Hereditary Cancer | Not recorded | Referenced |
|---|
| Concert Genetic Testing: Identity and Forensics | Not recorded | Referenced |
|---|
Showing 10 of 17 · All Regence BCBS policies
| Policy | Effective | Status of 81479 |
|---|---|---|
| Analysis of Human DNA or RNA in Stool Samples as a Technique for Colorectal Cancer Screening | May 1, 2026 | Covered |
| Chromosomal Microarray Analysis (CMA) or Copy Number Analysis for the Genetic Evaluation of Patients with Developmental Delay, Intellectual Disability, Autism Spectrum Disorder, or Congenital Anomalies | Aug 1, 2026 | Covered |
| Evaluating the Utility of Genetic Panels | Jul 1, 2026 | Covered |
| Expanded Molecular Testing of Cancers to Select Targeted Therapies | Jul 1, 2026 | Covered |
| Gene Expression-Based Assays for Cancers of Unknown Primary | Jun 1, 2026 | Covered |
| Genetic and Molecular Diagnostic Testing | Jun 1, 2026 | Covered |
| Genetic Testing for Biallelic RPE65 Variant-Associated Retinal Dystrophy | Jun 1, 2026 | Covered |
| Genetic Testing for Diagnosis and Management of Behavioral Health Conditions | Jul 1, 2026 | Covered |
| Genetic Testing for Epilepsy | Jan 1, 2026 | Covered |
| Genetic Testing for Macular Degeneration | Oct 1, 2025 | Covered |
| Policy | Effective | Status of 81479 |
|---|---|---|
| Carrier Testing Panels for Genetic Diseases – Surest Medical Policy | Aug 1, 2026 | Covered |
| Cell-Free Fetal DNA Testing | Oct 1, 2026 | Covered |
| Chromosome Microarray Testing (Non-Oncology Conditions) | Jun 1, 2026 | Covered |
| FDA Cleared or Approved Companion Diagnostic Testing | Jul 1, 2026 | Covered |
| Genetic Testing for Cardiac Disease | Sep 1, 2026 | Covered |
| Genetic Testing for Hereditary Cancer | Oct 1, 2026 | Covered |
| Genetic Testing for Neurological Disorders | Sep 1, 2026 | Covered |
| Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions | Aug 1, 2026 | Covered |
| Pharmacogenetic Panel Testing | Oct 1, 2026 | Covered |
| Preimplantation Genetic Testing and Related Services | May 1, 2026 | Covered |
| Policy | Effective | Status of 81479 |
|---|---|---|
| Carrier Testing Panels for Genetic Diseases | Jul 1, 2026 | Covered |
| Cell-Free Fetal DNA Testing | Oct 1, 2026 | Covered |
| Chromosome Microarray Testing (Non-Oncology Conditions) | Jun 1, 2026 | Covered |
| FDA Cleared or Approved Companion Diagnostic Testing | Jul 1, 2026 | Covered |
| Genetic Testing for Cardiac Disease | Sep 1, 2026 | Covered |
| Genetic Testing for Hereditary Cancer | Oct 1, 2026 | Covered |
| Genetic Testing for Neurological Disorders | Sep 1, 2026 | Covered |
| Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions | Aug 1, 2026 | Covered |
| Pharmacogenetic Panel Testing | Oct 1, 2026 | Covered |
| Preimplantation Genetic Testing and Related Services | May 1, 2026 | Covered |
| Policy | Effective | Status of 81479 |
|---|---|---|
| Carrier Testing Panels for Genetic Diseases | Jul 1, 2026 | Covered |
| Cell-Free Fetal DNA Testing | Oct 1, 2026 | Covered |
| Chromosome Microarray Testing (Non-Oncology Conditions) | Jun 1, 2026 | Covered |
| FDA Cleared or Approved Companion Diagnostic Testing | Jul 1, 2026 | Covered |
| Genetic Testing for Cardiac Disease | Sep 1, 2026 | Covered |
| Genetic Testing for Hereditary Cancer | Oct 1, 2026 | Covered |
| Genetic Testing for Neurological Disorders | Sep 1, 2026 | Covered |
| Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions | Aug 1, 2026 | Covered |
| Pharmacogenetic Panel Testing | Oct 1, 2026 | Covered |
| Preimplantation Genetic Testing and Related Services | May 1, 2026 | Covered |
| Policy | Effective | Status of 81479 |
|---|---|---|
| Carrier Screening in the Reproductive Setting | Sep 19, 2026 | Covered |
| Carrier Screening in the Reproductive Setting | Sep 20, 2025 | Covered |
| Genetic Liquid Biopsy in the Management of Cancer and Cancer Surveillance | Aug 22, 2026 | Covered |
| Genetic Liquid Biopsy in the Management of Cancer and Cancer Surveillance | Jun 14, 2026 | Covered |
| Hereditary Cancer Testing | Apr 4, 2026 | Covered |
| Pharmacogenetic Testing | Jun 14, 2026 | Covered |
| Predictive and Prognostic Polygenic Testing | Jun 14, 2026 | Covered |
| Prenatal Screening Using Cell Free Dna | Sep 19, 2026 | Covered |
| Prenatal Screening Using Cell Free Dna | Sep 20, 2025 | Covered |
| Policy | Effective | Status of 81479 |
|---|---|---|
| Molecular Signature Test for Predicting Response to Tumor Necrosis Factor Inhibitor Therapy | Oct 1, 2026 | Not covered |
| Protein Biomarkers for the Screening, Detection and Management of Prostate Cancer | Oct 1, 2026 | Not covered |
| Topographic Genotyping | Apr 15, 2026 | Not covered |
| Policy | Effective | Status of 81479 |
|---|---|---|
| Genetic Testing for Hematologic Malignancies and Suspected Myeloid Disorders | Sep 1, 2026 | Covered |
| Rheumatoid Arthritis: Biologic Markers and Pharmacologic Assessment | Oct 1, 2025 | Covered |
| Serological and Fecal Testing for Inflammatory Bowel Disease | Jun 1, 2026 | Covered with conditions |
| Policy | Effective | Status of 81479 |
|---|---|---|
| Cigna Comprehensive Code List | Mar 7, 2026 | Prior auth required |
| Policy | Effective | Status of 81479 |
|---|---|---|
| Molecular Pathology/Genetic Testing Reported with Unlisted Codes | Not recorded | Covered |